| Document |
Document Title |
|
WO/2023/085834A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
|
WO/2023/085835A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/085860A1 |
The present specification relates to a compound of chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2023/085789A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
|
WO/2023/085420A1 |
The present invention provides a means whereby it is possible to clarify the mechanism of manifestation of symptoms, an illness, or dysfunction caused by mitochondrial dysfunction and prevent or treat symptoms, an illness, or dysfunction...
|
|
WO/2023/081730A1 |
The present invention relates to 82 specific 4-hydroxy-2-oxo-1,2- dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid CB2 receptor modulators for the treatment of cancer, e.g. to 6-(4- fluorophenyl)-4-hydroxy-1-(2-(4-methy...
|
|
WO/2023/081209A1 |
Compounds of Formula (I) and pharmaceutically active salts thereof are provided, where the variables in Formula (I) are described herein. Such compounds and salts are PI3K inhibitors that are useful for treating conditions characterized ...
|
|
WO/2023/078812A1 |
The present invention relates to dicyano-substituted monoaza- or diazadibenzofurane derivatives and dicyano-substituted monoaza- or diazadibenzothiophene derivatives of the formula (1), wherein the following applies to the symbols and in...
|
|
WO/2023/077910A1 |
The present invention provides a preparation method for a curing agent composition, comprising the following steps: providing a first component and a second component; and mixing the first component and the second component, heating the ...
|
|
WO/2023/079993A1 |
An organic electroluminescent element having excellent properties can be provided by using a compound of the general formula. X represents O or S and R1 to R6 each represent H, D, an alkyl group, or an aryl group. Z1 and/or Z2 is a benzo...
|
|
WO/2023/072945A1 |
Compounds of the formula (I),wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and t...
|
|
WO/2023/070199A1 |
Methods and corresponding uses are provided for treating disease in a patient, involving the use of sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] so as to ameliorate drug resistance, including resistance to proteasome inhibi...
|
|
WO/2023/077070A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/076534A1 |
Disclosed are compounds that can be converted to mesembrenone under biologically relevant conditions, such as acid hydrolysis at body temperature; and related methods of preparing and using these compounds. Stable preparations of isolate...
|
|
WO/2023/071314A1 |
The present invention belongs to the field of medicinal chemistry, and particularly relates to synthesis, a preparation method and the use of an inhibitor containing dual targets SHP2 and CDK4/6, wherein the inhibitor comprises three com...
|
|
WO/2023/076849A1 |
Disclosed herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, that are inhibitors of inhibitors of epidermal growth factor receptor (EGFR), including EGFR C797S mutants. Also disclosed herein are pharmaceu...
|
|
WO/2023/072143A1 |
Disclosed in the present invention are a camptothecin derivative intermediate, and a preparation method therefor and the use thereof. The structural formula of the camptothecin derivative intermediate of the present invention is as shown...
|
|
WO/2023/014979A9 |
Provided herein are radiopharmaceutical compositions, conjugates and uses thereof. In one aspect, provided herein are covalently modified KRAS proteins comprising a radiolabeled compound or conjugate. In some embodiments, the radiolabele...
|
|
WO/2023/069708A1 |
Described herein, in part, are compounds that bind to and modulate the surface of cereblon and mediate the degradation of GSPT1, and are therefore useful in the treatment of various disorders, such as cancer.
|
|
WO/2023/066377A1 |
A compound represented by formula (I), a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of the pharmaceutically acceptable salt thereof, a preparation method therefor and an application thereof. The nitrogen-co...
|
|
WO/2023/061477A1 |
A new crystal form of a nitrogen-containing tricyclic compound and a use thereof, relating to a new crystal form of 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methox
y)-10H-spiro[benzo[6,7]oxazepine[3,2-b]pyridine-11,1'-cyclop...
|
|
WO/2023/064587A1 |
The present invention relates to 7,8-dihydro-5H-l,6-naphthyridine derivatives of formula (I) The present compounds are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in treating neurological...
|
|
WO/2023/061998A1 |
The present invention relates to diazabenzofurocarbazole derivatives and diazabenzothieonocarbazole derivatives and to electronic devices containing said compounds, in particular organic electroluminescent devices containing said compoun...
|
|
WO/2023/060362A1 |
There is provided a compound of formula (I), and its use for inhibiting RAS (wild type or mutant), for example HRAS, NRAS, and/or KRAS, and for the prevention or treatment of a disease or disorder associated with abnormal RAS activity, f...
|
|
WO/2023/063761A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/061468A1 |
Provided are a new crystal form and use of a nitrogenous tricyclic compound in the field of drugs. Specifically, the present invention relates to a new crystal form of 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-yl)metho
xy)-10H-...
|
|
WO/2023/061473A1 |
Disclosed is a new crystal form of compound 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-yl)metho
xy)-10H-spiro[benzo[6],7]oxazepine[3,2-b]pyridine-11,1'-cycl
opropane]-7-formic acid. The new crystal form is crystal form J. Furthe...
|
|
WO/2023/063697A1 |
The present invention relates to a series of novel pyrazolylmethylurea derivatives, and the use thereof for the inhibition of capsid assembly and the prevention or treatment of viral diseases through the inhibition.
|
|
WO/2023/061463A1 |
A pyrimidopyridine compound, a pharmaceutical composition thereof, and a use thereof. Specifically, the present invention relates to a compound represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a met...
|
|
WO/2023/057813A1 |
Disclosed herein are compounds, pharmaceutical compositions, and methods for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals. Compounds disclosed ...
|
|
WO/2023/056910A1 |
The present disclose includes, among other things, methods of preparing compound (R) -11: or a pharmaceutically acceptable salt thereof. Compound (R) -11 is useful to treat or lessen the severity of cancer.
|
|
WO/2023/057414A1 |
There are disclosed certain octahydrofuro[3,4-b]pyrazines of formula (la), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are GLP-1 receptor modulators an...
|
|
WO/2023/059546A1 |
Serotonin receptor agonists, including conformationally constrained serotonin receptor agonists, and methods of making and using the same are disclosed herein.
|
|
WO/2023/059739A1 |
The present disclose includes, among other things, compounds of formula (I) that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2023/057548A1 |
The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.
|
|
WO/2023/057896A1 |
Provided is a solvate that is 1-ethyl-3-((R)-3-((S)-2-hydroxy-3-(3- (methylsulfonyl)phenoxy)propylamino)-1-oxa-8-azaspiro[4.5]de
can-8-ylsulfonyl)quinolin-4(1H)- one mesylate hemihydrate Form 2, and pharmaceutical compositions thereof th...
|
|
WO/2023/055693A1 |
Turbinmicin analogs of Formula I are provided. Compositions including Turbinmicin analogs of Formula I, such as pharmaceutical compositions including effective amounts of Turbinmicin analogs of Formula I for treating fungal infections su...
|
|
WO/2023/056039A1 |
Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
|
|
WO/2023/051635A1 |
Disclosed in the present invention are a fused ring compound, and a preparation method therefor and the use thereof. Provided in the present invention are a fused ring compound as represented by formula I, a tautomer thereof, a stereoiso...
|
|
WO/2023/051490A1 |
Provided in the present invention is a pharmaceutical composition of a small molecular GLP-1R receptor agonist suitable for oral administration. More specifically, the present invention relates to a pharmaceutical composition containing ...
|
|
WO/2023/053009A1 |
The present invention relates to pyridines and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.
|
|
WO/2023/055017A1 |
The present specification provides a heterocyclic compound, an organic light-emitting device comprising same, a composition for an organic layer of an organic light-emitting device, and a method for manufacturing the organic light-emitti...
|
|
WO/2023/049364A1 |
The present disclosure is directed to compounds of formula (I):; wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates ...
|
|
WO/2023/049312A1 |
Disclosed herein are poymorph forms of (S)-N-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)me
thyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine.
|
|
WO/2023/046698A1 |
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therape...
|
|
WO/2023/049829A2 |
Described herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease.
|
|
WO/2023/046078A1 |
Disclosed are a novel pranoprofen derivative, and a pharmaceutical composition and use thereof. The novel pranoprofen derivative is as represented by formula (I0-1). The compound can be used for preparing a drug for treating diseases rel...
|
|
WO/2023/046939A1 |
The present invention relates to certain macrocyclic compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment or prevention of a disease associated with and/or caused by prot...
|
|
WO/2023/046034A1 |
A nitrogen-containing heterocyclic compound, a preparation method therefor, an intermediate thereof, and an application thereof. A nitrogen-containing heterocyclic compounds as shown in formula II-a, II-b, I-c, or I-d, a preparation meth...
|
|
WO/2023/039795A1 |
Provided is a novel compound of general formula (I) that inhibits RIP1 kinase or a pharmaceutically acceptable salt thereof. The present invention further relates to a composition containing such a compound, and the use of such a compoun...
|
